369 related articles for article (PubMed ID: 18394022)
1. Lipid-lowering therapy does not affect the postprandial drop in high density lipoprotein-cholesterol (HDL-c) plasma levels in obese men with metabolic syndrome: a randomized double blind crossover trial.
Hajer GR; Dallinga-Thie GM; van Vark-van der Zee LC; Olijhoek JK; Visseren FL
Clin Endocrinol (Oxf); 2008 Dec; 69(6):870-7. PubMed ID: 18394022
[TBL] [Abstract][Full Text] [Related]
2. The effects of low-dose simvastatin and ezetimibe compared to high-dose simvastatin alone on post-fat load endothelial function in patients with metabolic syndrome: a randomized double-blind crossover trial.
Olijhoek JK; Hajer GR; van der Graaf Y; Dallinga-Thie GM; Visseren FL
J Cardiovasc Pharmacol; 2008 Aug; 52(2):145-50. PubMed ID: 18670365
[TBL] [Abstract][Full Text] [Related]
3. The effect of statin alone or in combination with ezetimibe on postprandial lipoprotein composition in obese metabolic syndrome patients.
Hajer GR; Dallinga-Thie GM; van Vark-van der Zee LC; Visseren FL
Atherosclerosis; 2009 Jan; 202(1):216-24. PubMed ID: 18533158
[TBL] [Abstract][Full Text] [Related]
4. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.
Robinson JG; Ballantyne CM; Hsueh WA; Rosen JB; Lin J; Shah AK; Tomassini JE; Lowe RS; Tershakovec AM
J Clin Lipidol; 2013; 7(4):292-303. PubMed ID: 23890516
[TBL] [Abstract][Full Text] [Related]
5. Fasting cholesteryl ester transfer protein concentration is independently associated with the postprandial decrease in high-density lipoprotein cholesterol concentration after fat-rich meals: the Hoorn prandial study.
Alssema M; El-Harchaoui K; Schindhelm RK; Diamant M; Nijpels G; Kostense PJ; Teerlink T; Heine RJ; Dallinga-Thie GM; Kuivenhoven JA; Dekker JM; Scheffer PG
Metabolism; 2010 Jun; 59(6):854-60. PubMed ID: 20005542
[TBL] [Abstract][Full Text] [Related]
6. High-dose statin monotherapy versus low-dose statin/ezetimibe combination on fasting and postprandial lipids and endothelial function in obese patients with the metabolic syndrome: The PANACEA study.
Westerink J; Deanfield JE; Imholz BP; Spiering W; Basart DC; Coll B; Kastelein JJ; Visseren FL
Atherosclerosis; 2013 Mar; 227(1):118-24. PubMed ID: 23261174
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.
Davidson MH; Stein EA; Bays HE; Maki KC; Doyle RT; Shalwitz RA; Ballantyne CM; Ginsberg HN;
Clin Ther; 2007 Jul; 29(7):1354-67. PubMed ID: 17825687
[TBL] [Abstract][Full Text] [Related]
8. Effect of ezetimibe coadministration with simvastatin in a Middle Eastern population: a prospective, multicentre, randomized, double-blind, placebo-controlled trial.
Zubaid M; Shakir DK; Bazargani N; Binbrek A; Gopal R; Al-Tamimi O; Bakir S
J Cardiovasc Med (Hagerstown); 2008 Jul; 9(7):688-93. PubMed ID: 18545068
[TBL] [Abstract][Full Text] [Related]
9. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study.
Farnier M; Averna M; Missault L; Vaverkova H; Viigimaa M; Massaad R; Vandormael K; Johnson-Levonas AO; Brudi P
Int J Clin Pract; 2009 Apr; 63(4):547-59. PubMed ID: 19222610
[TBL] [Abstract][Full Text] [Related]
10. Effects of ezetimibe add-on to statin therapy on adipokine production in patients with metabolic syndrome and stable vascular disease.
Gupta M; Szmitko PE; Tsigoulis M; Braga MF; Kajil M; Herjikaka S; Quan A; Teoh H; Verma S
J Cardiovasc Pharmacol; 2010 Sep; 56(3):241-5. PubMed ID: 20505518
[TBL] [Abstract][Full Text] [Related]
11. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T
Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082
[TBL] [Abstract][Full Text] [Related]
12. Statin and fibrate combination does not additionally lower plasma cholesteryl ester transfer in type 2 diabetes mellitus.
de Vries R; Dikkeschei BD; Sluiter WJ; Dallinga-Thie GM; van Tol A; Dullaart RP
Clin Lab; 2012; 58(11-12):1231-9. PubMed ID: 23289194
[TBL] [Abstract][Full Text] [Related]
13. Post-prandial effects of gemfibrozil vs simvastatin in hypercholesterolemic subjects with borderline hypertriglyceridemia.
Vigna GB; Donega P; Passaro A; Zanca R; Cattin L; Fonda M; Pauciullo P; Marotta G; Fellin R; Gasparrini S; Piliego T
Nutr Metab Cardiovasc Dis; 1999 Oct; 9(5):234-43. PubMed ID: 10656170
[TBL] [Abstract][Full Text] [Related]
14. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
Guyton JR; Brown BG; Fazio S; Polis A; Tomassini JE; Tershakovec AM
J Am Coll Cardiol; 2008 Apr; 51(16):1564-72. PubMed ID: 18420099
[TBL] [Abstract][Full Text] [Related]
15. Reduction in estimated risk for coronary artery disease after use of ezetimibe with a statin.
Sampalis JS; Bissonnette S; Habib R; Boukas S;
Ann Pharmacother; 2007 Sep; 41(9):1345-51. PubMed ID: 17666579
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of simvastatin therapy in raising HDL-C in patients with type 2 diabetes and low HDL-C.
Miller M; Dobs A; Yuan Z; Battisti WP; Borisute H; Palmisano J
Curr Med Res Opin; 2004 Jul; 20(7):1087-94. PubMed ID: 15265253
[TBL] [Abstract][Full Text] [Related]
17. Simvastatin treatment on postprandial hypertriglyceridemia in type 2 diabetes mellitus patients with combined hyperlipidemia.
Sheu WH; Jeng CY; Lee WJ; Lin SY; Pei D; Chen YT
Metabolism; 2001 Mar; 50(3):355-9. PubMed ID: 11230791
[TBL] [Abstract][Full Text] [Related]
18. A deficiency of cholesteryl ester transfer protein whose serum remnant-like particle-triglyceride significantly increased, but serum remnant-like particle-cholesterol did not after an oral fat load.
Ai M; Tanaka A; Shimokado K; Ohtani R; Inazu A; Kobayashi J; Mabuchi H; Nakano T; Nakajima K
Ann Clin Biochem; 2009 Nov; 46(Pt 6):457-63. PubMed ID: 19641010
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin.
McKenney JM; Davidson MH; Shear CL; Revkin JH
J Am Coll Cardiol; 2006 Nov; 48(9):1782-90. PubMed ID: 17084250
[TBL] [Abstract][Full Text] [Related]
20. Cholesteryl ester transfer protein in metabolic syndrome.
Sandhofer A; Kaser S; Ritsch A; Laimer M; Engl J; Paulweber B; Patsch JR; Ebenbichler CF
Obesity (Silver Spring); 2006 May; 14(5):812-8. PubMed ID: 16855190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
